The occurrence of grade 3-4 infusion reactions was lower with panitumumab than with cetuximab ( one [ < 0.5 % ] patient vs nine [ 2 % ] patients ) , and the occurrence of grade 3-4 hypomagnesaemia was higher in the panitumumab group ( 35 [ 7 % ] vs 13 [ 3 % ] ) .